ArticleTheranostics2020
Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- MYC in Oncogenesis and Therapeutic Implications.MedComm · 2026Review
- Integrin-mediated mechanotransduction in the tumor microenvironment: macrophage-centered signaling mechanisms and immune remodeling.Journal of translational medicine · 2026Review
- Targeting Matrix Stiffness and Mechanotransduction in Breast Cancer: Implications for Emerging Therapies.International journal of molecular sciences · 2026Review
- Enhanced CHI3L1 promotes macrophage activation in persistent inflammatory events of ulcerative interstitial cystitis.Frontiers in immunology · 2026Article
- Preclinical Nanoparticle Approaches Targeting Tumor-Associated Macrophages in Breast Cancer: From Mechanisms to Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Nanomedicine-Based Strategies Targeting Macrophage Polarization in Breast Cancer Bone Metastasis: An Updated Review.Breast cancer (Dove Medical Press) · 2026Review
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
- Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance.Cell death discovery · 2025Review
- TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma.Bioactive materials · 2025Article
- Nanoparticles Modulating the Immune Microenvironment in Breast Cancer Treatment.International journal of nanomedicine · 2025Review
- Integrin-Specific Stimuli-Responsive Nanomaterials for Cancer Theranostics.Pharmaceutics · 2024Review
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert "Cold" Tumors to "Hot" Tumors.International journal of molecular sciences · 2024Review
- Transcription factors in fibroblast plasticity and CAF heterogeneity.Journal of experimental & clinical cancer research : CR · 2023Review
- The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development.Journal for immunotherapy of cancer · 2023Article
- Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems.Cancer medicine · 2023Review
- c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment.Cell communication and signaling : CCS · 2023Review
- Strategies to target the cancer driver MYC in tumor cells.Frontiers in oncology · 2023Review
- Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells.Frontiers in cell and developmental biology · 2023Review
- Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Alison K EsserDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Michael H RossDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Francesca FontanaDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Xinming SuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ariel GabayDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Gregory C FoxDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Yalin XuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jingyu XiangDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Anne H SchmiederDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Xiaoxia YangDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Grace CuiDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Michael ScottDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Samuel AchilefuDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Jay ChauhanDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.
Steven FletcherDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.
Gregory M LanzaDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Katherine N WeilbaecherDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Washington University in St. Louis · USMolecular Oncology (United States) · USUniversity of Maryland, Baltimore · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MProject 2 - Radiation-Induced Treatment of Multiple Myeloma using NanoparticlesU54CA199092 · NCI · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL, LANZA, GREGORY M · 2015 to 2019
$11.5MSkeletal Disorders Training ProgramT32AR060719 · NIAMS · WASHINGTON UNIVERSITY · PI Roberto Civitelli · 2011 to 2026
$4.6MOVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPYR01CA216840 · NCI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, WEILBAECHER, KATHERINE NELSON · 2018 to 2022
$3.1MWHOLE SLIDE IMAGING SYSTEM FOR TRANSLATIONAL NEUROSCIENCES10RR027552 · NCRR · WASHINGTON UNIVERSITY · PI LEE, JIN-MOO · 2010 to 2010
$275kNCI NIH HHS P30 CA091842NCI NIH HHS R01 CA216840NCI NIH HHS U54 CA199092NCRR NIH HHS S10 RR027552NIAMS NIH HHS T32 AR060719
Abstract
Tumor-associated macrophages (TAMs) enhance tumor growth in mice and are correlated with a worse prognosis for breast cancer patients. While early therapies sought to deplete all macrophages, current therapeutics aim to reprogram pro-tumor macrophages (M2) and preserve those necessary for anti-tumor immune responses (M1). Recent studies have shown that c-MYC (MYC) is induced in M2 macrophages
Indexed as
AnimalsAntineoplastic AgentsBreast NeoplasmsCarcinogenesisCell Line, TumorDrug Evaluation, PreclinicalFemaleFluorocarbonsGene Knockout TechniquesHumansIntegrin alphaVbeta3Integrin beta3MacrophagesMammary Neoplasms, ExperimentalMiceNanoparticlesAntineoplastic AgentsFluorocarbonsIntegrin alphaVbeta3Integrin beta3Myc protein, mouseProdrugsProto-Oncogene Proteins c-mycbreast cancerdrug deliverymacrophagesMYCnanoparticlesβ3 integrin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.